title: Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.
abstract: BACKGROUND
  We investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone.
  
  
  METHODS
  Eligible patients had coronary artery disease and Lp(a) levels > or =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods.
  
  
  RESULTS
  A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P<0.0001); the corresponding mean annual MACE rate per patient was 1.056 versus 0.144 (P<0.0001).
  
  
  CONCLUSIONS
  Lowering of Lp(a) levels by apheresis was efficacious and safe, and we recommend this therapy for patients in whom maximally tolerated doses of medication alone have failed to control coronary artery disease-associated events.
authors.affiliation: Labor Dr Stein und Kollegen, Medizinisches Versorgungszentrum Laboratoriumsmedizin, Mikrobiologie, Infektionsepidemiologie, Virologie, Transfusionsmedizin und Humangenetik, Mönchengladbach, Germany. drbjaeger@web.de
authors.forename: Beate R
authors.initials: BR
authors.lastname: Jaeger
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Richter
authors.forename: Dorothea
authors.initials: D
authors.lastname: Nagel
authors.forename: Franz
authors.initials: F
authors.lastname: Heigl
authors.forename: Anja
authors.initials: A
authors.lastname: Vogt
authors.forename: Eberhard
authors.initials: E
authors.lastname: Roeseler
authors.forename: Klaus
authors.initials: K
authors.lastname: Parhofer
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Ramlow
authors.forename: Michael
authors.initials: M
authors.lastname: Koch
authors.forename: Gerd
authors.initials: G
authors.lastname: Utermann
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Labarrere
authors.forename: Dietrich
authors.initials: D
authors.lastname: Seidel
mesh_terms: D000328:Adult; D000368:Aged; D001781:Blood Component Removal; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017270:Lipoprotein(a) / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D017270:Lipoprotein(a)